Why
Liposomal
Amphotericin
B
Liposomal
Amphotericin
B
Why Liposomal Amphotericin B
I Am… Liposomal Amphotericin B: Ready to
help Fatima fight her breakthrough IFI11
help Fatima fight her breakthrough IFI11
Liposomal Amphotericin B was chosen alongside
voriconazole to help treat Fatima's Rhizopus CNS
infection, due to its:
voriconazole to help treat Fatima's Rhizopus CNS
infection, due to its:
Activity against a broad spectrum
of fungal pathogens12–15
of fungal pathogens12–15
Liposomal Amphotericin B has a broad spectrum
of in vitro activity against the most common fungal
pathogens, including those causing rare and
difficult‑to‑treat infections (e.g. azole‑resistant
strains).12–14,17
of in vitro activity against the most common fungal
pathogens, including those causing rare and
difficult‑to‑treat infections (e.g. azole‑resistant
strains).12–14,17
Low risk of resistance15,18–21
After more than 50 years of clinical use, acquired
resistance to amphotericin B, the active ingredient
in Liposomal Amphotericin B, has rarely been
reported.15,18–21
resistance to amphotericin B, the active ingredient
in Liposomal Amphotericin B, has rarely been
reported.15,18–21
Well-established tolerability and
safety profile*11
safety profile*11
Very common adverse events associated with
Liposomal Amphotericin B treatment include rigors,
pyrexia, hypokalaemia, nausea and vomiting.11
Liposomal Amphotericin B treatment include rigors,
pyrexia, hypokalaemia, nausea and vomiting.11
*Please refer to the Liposomal Amphotericin B Summary of Product Characteristics for detailed information on safety profile.
DAY 9-11
Treatment initiation
DAY 13-18
No improvement
